Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009

Wilbur H Chen, Patricia L Winokur, Kathryn M Edwards, Lisa A Jackson, Anna Wald, Emmanuel B Walter, Diana L Noah, Mark Wolff, Karen L Kotloff, Pandemic H1N1 Vaccine Adult Study Group, Joel V Chua, Julia Hutter, Ina Stephens, Jack Stapleton, Jeff Meier, S Todd Callahan, C Buddy Creech, Natasha B Halasa, Christine Johnston, Rowena J Dolor, Kenneth E Schmader, Christopher W Woods, Heather Hill, Wilbur H Chen, Patricia L Winokur, Kathryn M Edwards, Lisa A Jackson, Anna Wald, Emmanuel B Walter, Diana L Noah, Mark Wolff, Karen L Kotloff, Pandemic H1N1 Vaccine Adult Study Group, Joel V Chua, Julia Hutter, Ina Stephens, Jack Stapleton, Jeff Meier, S Todd Callahan, C Buddy Creech, Natasha B Halasa, Christine Johnston, Rowena J Dolor, Kenneth E Schmader, Christopher W Woods, Heather Hill

Abstract

Background: The influenza A/H1N1 pandemic in 2009 created an urgent need to develop vaccines for mass immunization. To guide decisions regarding the optimal immunization dosage and schedule for adults, we evaluated two monovalent, inactivated, unadjuvanted H1N1 influenza vaccines in independent, but simultaneously conducted, multi-center Phase 2 trials of identical design.

Methods: Healthy adults, stratified by age (18-64 years and ≥65 years), were randomized (1:1 allocation), in a double-blind, parallel-group design, to receive two intramuscular doses (21 days apart) of vaccine containing approximately 15 μg or 30 μg of hemagglutinin (HA). Primary endpoints were safety (reactogenicity for 8 days after each vaccination and vaccine-associated serious adverse events during the 7 month study) and immunogenicity (proportion of subjects, stratified by age, achieving a serum hemagglutination inhibition [HI] antibody titer ≥1:40 or a ≥4-fold rise in titer after a single injection of either dosage).

Results: Both vaccines were well-tolerated. A single 15 μg dose induced HI titers ≥1:40 in 90% of younger adults (95% confidence interval [CI] 82-95%) and 81% of elderly (95% CI 71-88%) who received Sanofi-Pasteur vaccine (subsequently found to contain 24 μg HA in the standard potency assay), and in 80% of younger adults (95% CI 71-88%) and 60% of elderly (95% CI 50-70%) who received CSL vaccine. Both vaccines were significantly more immunogenic in younger compared with elderly adults by at least one endpoint measure. Increasing the dose to 30 μg raised the frequency of HI titers ≥1:40 in the elderly by approximately 10%. Higher dosage did not significantly enhance immunogenicity in younger adults and a second dose provided little additional benefit to either age group.

Conclusion: These trials provided evidence for policymakers that a single 15 μg dose of 2009 A/H1N1 vaccine would likely protect most U.S. adults and suggest a potential benefit of a 30 μg dose for the elderly.

Trial registration: ClinicalTrials.gov NCT00943488 NCT00943631.

Conflict of interest statement

Conflicts of Interest

WHC has been a paid consultant to AlphaVax, LigoCyte Pharmaceuticals, Integrated BioTherapeutics, Toyama Chemical Co, and Functional Genetics. KME has received funding from the National Institutes of Health and the CDC to evaluate the impact of influenza vaccines and study new influenza vaccines, and has received funding from PATH through the Bill & Melinda Gates Foundation (BMGF) to evaluate potential new influenza vaccines. KLK receives funding from the BMGF to evaluate maternal influenza vaccines. LAJ has received research funding from GSK, Sanofi-Pasteur, Novartis Vaccines and Pfizer. EBW has served as an advisor, consultant, and speaker for Merck vaccines, an advisor to Novartis vaccines, a speaker for Sanofi-Pasteur, and has received funding as an investigator evaluating influenza vaccines for Medimmune and Sanofi-Pasteur. KES has received grant support from the VA and Merck for zoster vaccine studies, from Wyeth for pneumococcal vaccine studies and from NIAID for influenza vaccine studies. RJD has received funding as an investigator evaluating influenza vaccines for CSL. The remaining authors have no conflicts of interest.